Abstract:However, increasing research has revealed that the impact of COVID-19 on children is particularly noteworthy, as they were initially thought to be less susceptible to severe outcomes compared to adults. It has been observed that pulmonary involvement in children can be more severe than in adults, and numerous case reports have highlighted the occurrence of multisystem involvement. Clinical treatment and management approaches for pediatric patients cannot solely rely on data derived from adult cases 2 . This editorial aimed to synthesize the latest research findings to explore the impact of COVID-19 on children, including conditions such as acute necrotizing encephalopathy (ANE), aseptic meningoencephalitis (ME), febrile seizures (FSs), and multisystem inflammatory syndrome in children (MIS-C). These findings underscore the need for heightened awareness among healthcare providers.As the COVID-19 pandemic has progressed, different SARS-CoV-2 variants have led to varying clinical presentations. Initially, children infected with SARS-CoV-2 exhibited mild respiratory symptoms. However, in later stages of the pandemic, particularly in patients infected with the Delta and Omicron variants, more life-threatening nonrespiratory complications have emerged 3,4 . When clinical symptoms closely resemble other diseases, it can be challenging to make an accurate diagnosis promptly.Multisystem inflammatory syndrome in children (MIS-C) is a systemic inflammatory syndrome that may occur in children following infection with SARS-CoV-2. The early clinical presentation of MIS-C is quite similar to Kawasaki disease, often presenting with symptoms such as fever, conjunctival injection, and rash 5 . MIS-C has been reported mainly in Western countries; however, the incidence of MIS-C appears to be lower in Asian regions 6 . According to a previous study, among 137 patients with MIS-C, only 4 (2.5%) exhibited symptoms of posterior pharyngeal swelling. If such cases occur in Asian regions where the incidence of MIS-C is lower and the incidence of Kawasaki disease is higher, clinicians should assess the risk of MIS-C in their patients 7 . Both conditions can cause inflammation in multiple organ systems, requiring different management approaches. Therefore, it is crucial for clinicians to accurately diagnose and differentiate these conditions, especially when rare clinical symptoms, such as retropharyngeal edema, are present.A few case reports have noted that patients with MIS-C may present with retropharyngeal edema. For example, a case report from Japan (Takanori Suzuki et al., 2023) described a previously healthy nine-year-old boy who developed severe retropharyngeal edema resistant to intensive antibiotic treatment. Enhanced CT imaging revealed typical findings of the disease. Throat swabs and blood cultures performed during the initial examination were negative; however, records indicated a COVID-19 infection three weeks prior to the onset of symptoms. The patient, aged nine, which is a common age for MIS-C onset, experienced rapid symptom resolution and normalization of laboratory data following intravenous immunoglobulin treatment.This case, along with previous reports 7 , suggests that early use of intravenous immunoglobulin may help prevent the progression of MIS-C and the occurrence of circulatory failure. Additionally, retropharyngeal edema might be used as a predictor for MIS-C. For febrile children with severe neck symptoms and retropharyngeal edema, if MIS-C is suspected, recent COVID-19 history should be assessed, and early intervention may prevent disease progression.According to the research conducted by Dr. Liliane N. Byamungu and colleagues (Byamungu et al., 2023), the occurrence of cytokine storms indicates immune dysregulation. If not promptly addressed, this condition can lead to significant morbidity and mortality, particularly in regions with limited medical resources and among children with human immunodeficiency virus (HIV) infection, such as in Africa.Previous studies have shown that the incidence and mortality rates of COVID-19 among hospitalized children and adolescents in these areas are significantly higher than in non African regions 9 . These risks are associated with being under 1 year of age and with selected non communicable comorbidities, such as chronic kidney disease, chronic lung disease, blood disorders, liver disease, and chronic neurological conditions.Moreover, children living in regions with high HIV prevalence or those exposed to HIV face a higher risk of severe COVID-19. This underscores the severity of COVID-19 among children with underlying medical conditions. Additionally, the results indicate that children with a history of comorbid conditions face a higher risk of severe disease and mortality, with HIV exposure and younger age being significant predictors.The impact of COVID-19 on healthcare support systems is substantial, particularly -Abstract Truncated-

Elucidating systemic immune responses to acute and convalescent SARS‐CoV‐2 infection in children and elderly individuals

Differences In Clinical Features And Laboratory Results Between Adults And Children With Sars-Cov-2 Infection

Innate cell profiles during the acute and convalescent phase of SARS-CoV-2 infection in children

Mild Cytokine Elevation, Moderate CD4+ T Cell Response and Abundant Antibody Production in Children with COVID-19

The Immunological Profile of SARS-CoV-2 Infection in Children Is Linked to Clinical Severity and Age

Systems serology detects functionally distinct coronavirus antibody features in children and elderly

Reduced Inflammatory Responses to SARS-CoV-2 Infection in Children Presenting to Hospital with COVID-19 in China

Immunological characterization and comparison of children with COVID-19 from their adult counterparts at single-cell resolution

Age-related Differences in the Nasal Mucosal Immune Response to SARS-CoV-2

The Effect of Age and Comorbidities: Children vs. Adults in Their Response to SARS-CoV-2 Infection

Characteristics of Immune and Inflammatory Responses among Different Age Groups of Pediatric Patients with COVID-19 in China.

Severe pediatric COVID-19: a review from the clinical and immunopathophysiological perspectives

Clinical features of Chinese children with COVID‐19 and other viral respiratory infections

Comparison of Clinical and Para-Clinical Characteristics Between Children and Adults with the Omicron Variant of COVID-19

Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19

Characteristics of innate, humoral and cellular immunity in children with non-severe SARS-CoV-2 infection

Editorial: Ethnic differences in children in the clinical manifestation of infection with SARS-Cov-2 and its variants

Early Immune Responses and Prognostic Factors in Children with COVID-19: a Single-Center Retrospective Analysis

Distinct Disease Severity Between Children and Older Adults With Coronavirus Disease 2019 (COVID-19): Impacts of ACE2 Expression, Distribution, and Lung Progenitor Cells

Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China

The kinetics and durability of antibody and T-cell responses to SARS-CoV-2 in children